Core Viewpoint - The A-share market is experiencing a strong performance in flu-related stocks, driven by expectations of a flu outbreak in the upcoming winter season [1] Group 1: Market Performance - Flu concept stocks in the A-share market have shown significant gains, with Te Yi Pharmaceutical hitting the daily limit, Tai Long Pharmaceutical and Nanxin Pharmaceutical rising over 7%, Weikang Pharmaceutical increasing over 5%, and Peking University Pharmaceutical up nearly 4% [1] - Yiling Pharmaceutical has also seen an increase of almost 4% [1] Group 2: Health Forecast - The China Center for Disease Control and Prevention (CDC) predicts that the peak of the flu epidemic in China this autumn and winter may occur in mid-December to early January [1] - The CDC is actively monitoring and assessing flu activity across the country, indicating that the overall flu activity in China is currently on the rise [1] - The H3N2 subtype of the influenza virus accounts for over 95% of the cases, with a small presence of H1N1 and B-type influenza viruses circulating simultaneously [1]

Core Viewpoint - The flu sector has experienced a significant rally, with notable stock price increases among several pharmaceutical companies [1] Company Summaries - Special One Pharmaceutical has reached its daily limit increase in stock price [1] - Nanxin Pharmaceutical's stock has risen by over 6% [1] - Tailong Pharmaceutical, Hendi Pharmaceutical, and Zhongsheng Pharmaceutical have also seen stock price increases [1]

Core Viewpoint - Company announced a share buyback program, indicating confidence in its financial health and future prospects [2] Group 1 - As of October 31, 2025, the company has repurchased a total of 357,179 shares [2] - The repurchased shares represent 0.13% of the company's total share capital of 274,400,000 shares [2]

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 357,200 shares, which represents 0.13% of its total share capital of 274 million shares [1] - The highest price paid for the repurchased shares was 7.97 CNY per share, while the lowest price was 7.02 CNY per share [1] - The total amount spent on the buyback was 2.6962 million CNY, excluding transaction fees such as stamp duty and commissions [1]

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. reported a significant decline in revenue and increasing net losses for the first three quarters of 2025, attributed to intensified market competition and reduced influenza cases [1][2]. Financial Performance - For the first three quarters of 2025, Nanxin Pharmaceutical achieved total revenue of 83.15 million yuan, a year-on-year decrease of 66.89% [1] - The net loss attributable to shareholders was 68.63 million yuan, compared to a loss of 57.22 million yuan in the same period last year [1] - Historical revenue from 2020 to 2024 shows a downward trend, with revenues of 1.03 billion yuan in 2020, dropping to 263 million yuan in 2024 [1] Product Competition - The core product, Palivizumab Sodium Injection, faces increased competition as multiple competitors have entered the market, leading to a significant drop in sales [2] - The company has implemented a price reduction strategy, lowering the price of Palivizumab Sodium Injection by 43.51% in 2023 to maintain market share [2] Acquisition Attempts - In August 2025, Nanxin Pharmaceutical announced plans to acquire assets from Future Pharmaceutical for up to 480 million yuan, aiming to diversify its product line [4] - The acquisition was intended to enhance the company's product matrix and provide short-term revenue growth, but it was terminated on September 30 due to failure to agree on key terms [4] Regulatory and Internal Challenges - The company faces challenges related to weak financial internal controls and regulatory investigations, including a notice from the China Securities Regulatory Commission regarding potential violations of information disclosure [5] - A prior accounting error led to a revenue adjustment of 24.54 million yuan for 2023, highlighting internal control weaknesses [5]

（记者 曾健辉） 每经头条（nbdtoutiao）——"为了孩子吃上饭，自己只能靠喝水撑着"！美政府停摆危机逼近"临界 点"，4200万人吃饭成问题 每经AI快讯，南新制药11月3日晚间发布公告称，截至2025年10月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式累计回购公司股份约36万股，占公司总股本约2.74亿股的比例为0.13%，回购 成交的最高价为7.97元/股，最低价为7.02元/股，支付的资金总额为人民币约270万元。 ...

重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 357,179股 | | 累计已回购股数占总股本比例 | 0.13% | | 累计已回购金额 | 2,696,235.78元 | | 实际回购价格区间 | 7.02元/股~7.97元/股 | 证券代码：688189 证券简称：南新制药 公告编号：2025-051 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 10 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购公 司股份 91,663 股，占公司总股本 274,400,000 股的比例为 0.03% ...

Core Insights - Nanjing Pharmaceutical focuses on antiviral and major disease treatment drug research and development, with strong technical capabilities in the prevention and treatment of infectious diseases like influenza [1] Financial Performance - For Q3 2025, Nanjing Pharmaceutical reported revenue of 83.15 million yuan, ranking 106th among 110 companies in the industry, significantly lower than the industry leader, East China Pharmaceutical, which reported 32.664 billion yuan [2] - The company's net profit was -75.78 million yuan, ranking 90th in the industry, far behind the top performers, Heng Rui Pharmaceutical at 5.76 billion yuan and Fosun Pharmaceutical at 3.056 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 22.57%, an increase from 11.61% in the same period last year, but still below the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 33.44%, a significant decline from 60.76% in the previous year and below the industry average of 57.17% [3] Executive Compensation - The chairman and general manager, Zhang Shixi, received a salary of 735,500 yuan in 2024, a decrease of 272,700 yuan from 1,008,200 yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 49.13% to 14,100, while the average number of circulating A-shares held per shareholder decreased by 32.95% to 19,400 [5] - New major shareholders include several funds from GF Fund Management, with notable holdings of 5.4741 million shares, 5.3492 million shares, 3.8594 million shares, and 1.5945 million shares [5]

格隆汇10月30日丨南新制药(688189.SH)发布三季报，2025年前三季度实现营业总收入8315.44万元，同 比下降66.89%；归属母公司股东净利润-6863.38万元，较上年同期亏损增加1141.79万元；基本每股收益 为-0.2501元。 ...

Financial Performance - The company's operating revenue for the third quarter was ¥21,308,086.94, a decrease of 40.45% compared to the same period last year[3]. - The total profit for the third quarter was -¥32,149,686.43, with a year-to-date total profit of -¥76,118,300.93, reflecting significant losses[3]. - The net profit attributable to shareholders for the third quarter was -¥28,631,491.51, down from -¥67,388,600.15 in the previous year[3]. - Total operating revenue for the first three quarters of 2025 was CNY 83,154,434.61, a decrease of 66.9% compared to CNY 251,110,585.69 in the same period of 2024[19]. - Net loss for the first three quarters of 2025 was CNY 75,777,289.57, compared to a net loss of CNY 65,925,432.36 in the same period of 2024, indicating a worsening of 14.1%[20]. - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.2501, compared to CNY -0.2089 in 2024, indicating a decline in earnings performance[21]. Research and Development - Research and development expenses totaled ¥9,746,614.10 for the third quarter, a decrease of 61.66% year-over-year, with R&D expenses accounting for 45.74% of operating revenue[3]. - Research and development expenses for the first three quarters of 2025 were CNY 27,300,905.81, slightly up from CNY 26,325,369.38 in 2024, representing an increase of 3.7%[20]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥75,223,063.51, an increase of 149.83% compared to the previous year[3]. - Cash received from sales of goods and services in the first three quarters of 2025 was CNY 186,545,063.10, down from CNY 257,971,161.66 in 2024, a decrease of 27.6%[23]. - Cash received from other operating activities was $18,955,390.12, up from $12,103,123.17, indicating improved operational cash generation[24]. - The ending cash and cash equivalents balance was $422,663,108.40, compared to $388,506,660.17 previously, showing a slight increase in liquidity[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,033,888,431.00, a decrease of 15.42% from the previous year-end[4]. - The total liabilities decreased from CNY 344,132,614.55 in 2024 to CNY 233,328,012.55 in 2025, a reduction of 32.2%[16]. - The total equity attributable to shareholders decreased from CNY 936,592,121.87 in 2024 to CNY 865,990,145.96 in 2025, a decline of 7.5%[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,114[8]. - Hunan Pharmaceutical Development Investment Group Co., Ltd. holds 28.57% of shares, totaling 78,400,000 shares[9]. - The company has repurchased a total of 265,516 shares, representing 0.10% of the total share capital, with a total expenditure of RMB 1,967,393.92[11]. Market Conditions - The company is currently facing increased market competition, which has significantly impacted sales and revenue[6]. Accounting and Reporting - The company identified an accounting error that reduced 2023 revenue by ¥24,539,700, representing 3.4% of total revenue for that year[4]. - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[26].